Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARS1 | P26639 | 2/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435121 | 1.00 | TARS1 (0.38) | TARS1SLC29A1ADORA1LMNATP53 | |
| SCHEMBL28564130 | 1.00 | TARS1 (0.38) | TARS1SLC29A1ADORA1LMNATP53 | |
| SCHEMBL29089525 | 0.88 | TARS1 (0.39) | TARS1SLC29A1ADORA1 | |
| SCHEMBL28475028 | 0.87 | SLC29A1 (0.46) | SLC29A1ADORA1LMNATP53ALOX15 | |
| SCHEMBL26090156 | 0.86 | HTR2B (0.35) | TARS1ADORA1 | |
| SCHEMBL29413061 | 0.86 | HTR2B (0.35) | TARS1ADORA1 | |
| SCHEMBL28300819 | 0.85 | ADORA3 (0.35) | TARS1ADORA1 | |
| SCHEMBL30950292 | 0.85 | TARS1 (0.37) | TARS1SLC29A1ADORA1 | |
| SCHEMBL31675871 | 0.84 | AHCY (0.41) | ADORA1 | |
| SCHEMBL17627818 | 0.84 | RXFP1 (0.39) | SLC29A1ADORA1LMNATP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119768532-A | Method for producing nucleic acid | 辉瑞公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2025054355-A1 | METHODS, SYSTEMS, AND COMPOSITIONS FOR EXOGENOUS CONTROL OF PROTEIN EXPRESSION | RADAR THERAPEUTICS INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-118201625-A9 | Microalgae extracellular vesicles, preparation and use thereof | AGS治疗简易股份公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118201625-A | Microalgae extracellular vesicles, preparation and use thereof | AGS治疗简易股份公司 | 2024-06-14 | — | — | CN | disclosed |
| US-11884937-B2 | Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mRNA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-01-30 | — | — | US | disclosed |
| CN-116113696-A | Gene editing to improve joint function | 奥泽生物疗法公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230045590-A1 | GENETICALLY CORRECTED CELLS FOR THERAPEUTIC USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| EP-3991751-A1 | ACTIVATION OF INNATE IMMUNITY FOR ENHANCED NUCLEAR REPROGRAMMING OF SOMATIC CELLS WITH MRNA | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3104889-B1 | ACTIVATION OF INNATE IMMUNITY FOR ENHANCED NUCLEAR REPROGRAMMING OF SOMATIC CELLS WITH MRNA | UNIV LELAND STANFORD JUNIOR (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2021133724-A1 | GENETICALLY CORRECTED CELLS FOR THERAPEUTIC USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210130792-A1 | ACTIVATION OF INNATE IMMUNITY FOR ENHANCED NUCLEAR REPROGRAMMING OF SOMATIC CELLS WITH mRNA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-05-06 | — | — | US | disclosed |
| US-10760061-B2 | Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mRNA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| US-9738873-B2 | Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mRNA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170204376-A1 | ACTIVATION OF INNATE IMMUNITY FOR ENHANCED NUCLEAR REPROGRAMMING OF SOMATIC CELLS WITH mRNA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-07-20 | — | — | US | disclosed |
| EP-3104889-A1 | ACTIVATION OF INNATE IMMUNITY FOR ENHANCED NUCLEAR REPROGRAMMING OF SOMATIC CELLS WITH mRNA | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20150225699-A1 | ACTIVATION OF INNATE IMMUNITY FOR ENHANCED NUCLEAR REPROGRAMMING OF SOMATIC CELLS WITH mRNA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | disclosed |
| WO-2015120225-A1 | ACTIVATION OF INNATE IMMUNITY FOR ENHANCED NUCLEAR REPROGRAMMING OF SOMATIC CELLS WITH mRNA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-08-13 | — | — | WO | disclosed |